Medroxyprogesterone acetate (MAP) plasma levels after multiple high-dose administration in advanced cancer patients
Cancer Chemotherapy and Pharmacology1983Vol. 11(1), pp. 19–22
CarloMaurizio Camaggi, Elena Strocchi, M Giovannini, Bruna Angelelli, Barbara Costanti, Emanuela Zebini, Patrizio Ferrari, F Pannuti
Related Papers
- → Retrospective study on the effectiveness of medroxyprogesterone acetate in the treatment of ER-positive/HER2-negative post-menopausal advanced breast cancer: an additional analysis of the JBCRG-C06 Safari study(2022)3 cited
- → Depo-Provera effects on Wistar rat performance in the Y-maze(2013)9 cited
- → 91240488 Bone density in women receiving depot medroxyprogesterone acetate for contraception(1992)9 cited
- New trends in the use of medroxyprogesterone acetate as a chemotherapeutic agent in gynecologic malignancies.(1992)
- [Possible indications for medroxyprogesterone in the management of breast cancer].(1980)